MCID: AMP007
MIFTS: 39

Amphetamine Abuse

Categories: Mental diseases

Aliases & Classifications for Amphetamine Abuse

MalaCards integrated aliases for Amphetamine Abuse:

Name: Amphetamine Abuse 12 56 15
Amphetamine-Related Disorders 45

Classifications:



External Ids:

Disease Ontology 12 DOID:670
ICD9CM 36 305.7
MeSH 45 D019969
UMLS 74 C0154536

Summaries for Amphetamine Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of amphetamines despite negative consequences.

MalaCards based summary : Amphetamine Abuse, also known as amphetamine-related disorders, is related to premature ejaculation and alcohol-induced mental disorder. An important gene associated with Amphetamine Abuse is SLC6A3 (Solute Carrier Family 6 Member 3), and among its related pathways/superpathways are Circadian entrainment and Taste transduction. The drugs Amphetamine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, and related phenotypes are behavior/neurological and cellular

Related Diseases for Amphetamine Abuse

Diseases related to Amphetamine Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 33)
# Related Disease Score Top Affiliating Genes
1 premature ejaculation 10.3 HTR1B SLC6A3
2 alcohol-induced mental disorder 10.2 NPS SLC6A3
3 oppositional defiant disorder 10.2 SLC6A2 SLC6A3
4 alcoholic psychosis 10.2 NPS SLC6A3
5 pathological gambling 10.2 MAOB SLC6A3
6 myocardial infarction 10.1
7 acute myocardial infarction 10.1
8 antisocial personality disorder 10.1 HTR1B MAOB SLC6A3
9 mood disorder 10.1 HTR1B MAOB SLC6A2
10 abducens nerve disease 10.1 IVD KANTR
11 postencephalitic parkinson disease 10.1 KANTR MAOB
12 brunner syndrome 10.1 HTR1B MAOB
13 oculogyric crisis 10.1 KANTR MAOB
14 arteriovenous malformation 10.1
15 major depressive disorder 10.0 GRM5 HTR1B SLC6A2 SLC6A3
16 nervous system disease 10.0 KANTR MAOB SLC6A3
17 dystonia 1, torsion, autosomal dominant 10.0 KANTR MAOB
18 migraine with or without aura 1 9.9 HTR1B KANTR NPS
19 hemorrhage, intracerebral 9.9
20 holoprosencephaly 9.9
21 thrombosis 9.9
22 transsexualism 9.9
23 patau syndrome 9.9
24 superior mesenteric artery syndrome 9.9
25 mucormycosis 9.9
26 parkinson disease, late-onset 9.9 GRM5 MAOB NTS SLC6A3
27 neurodermatitis 9.9 KANTR NPS
28 attention deficit-hyperactivity disorder 9.8 GRM5 HTR1B MAOB SLC6A2 SLC6A3
29 intraocular retinoblastoma 9.8 KANTR PVALB
30 central nervous system disease 9.7 GRM2 GRM5 MAOB SLC6A2 SLC6A3
31 agraphia 9.7 KANTR MAPK14
32 disease of mental health 9.2 GRM2 GRM5 NPS PVALB SLC6A2 SLC6A3
33 schizophrenia 8.9 GRM2 GRM5 HTR1B MAOB NTS PVALB

Graphical network of the top 20 diseases related to Amphetamine Abuse:



Diseases related to Amphetamine Abuse

Symptoms & Phenotypes for Amphetamine Abuse

MGI Mouse Phenotypes related to Amphetamine Abuse:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.9 ARC GRM2 GRM5 HTR1B MAOB MAPK14
2 cellular MP:0005384 9.61 GRM2 HTR1B ITK MAOB MAP3K5 MAPK14
3 nervous system MP:0003631 9.32 ARC GRM2 GRM5 MAOB MAPK14 NTS

Drugs & Therapeutics for Amphetamine Abuse

Drugs for Amphetamine Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 119)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 300-62-9 3007 5826
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
3
Cocaine Approved, Illicit Phase 4,Not Applicable 50-36-2 446220 5760
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5 Dopamine Antagonists Phase 4,Phase 3,Phase 1
6 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Sympathomimetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Vasoconstrictor Agents Phase 4
23 Quetiapine Fumarate Phase 4 111974-72-2
24 Anesthetics Phase 4
25 Anesthetics, Local Phase 4
26
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-67-9 5202
27
Mirtazapine Approved Phase 3,Phase 2,Not Applicable 85650-52-8, 61337-67-5 4205
28
Histamine Approved, Investigational Phase 3,Phase 2,Not Applicable 51-45-6 774
29
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
30
Naltrexone Approved, Investigational, Vet_approved Phase 3,Phase 2 16590-41-3 5360515
31
Ethanol Approved Phase 3,Phase 2,Phase 1 64-17-5 702
32 Histamine H1 Antagonists Phase 3,Phase 2,Not Applicable
33 Analgesics, Opioid Phase 3
34 Adrenergic Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
35
Histamine Phosphate Phase 3,Phase 2,Not Applicable 51-74-1 65513
36 Serotonin 5-HT3 Receptor Antagonists Phase 3,Phase 2,Not Applicable
37 Serotonin 5-HT2 Receptor Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
38 Adrenergic alpha-Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
39 Anti-Anxiety Agents Phase 3,Phase 2,Not Applicable
40 Histamine Antagonists Phase 3,Phase 2,Not Applicable
41 Paliperidone Palmitate Phase 3
42 Dopamine D2 Receptor Antagonists Phase 3,Phase 1
43 Anti-Infective Agents Phase 3,Phase 2,Phase 1
44 Anti-Bacterial Agents Phase 3
45 Narcotic Antagonists Phase 3,Phase 2
46 Narcotics Phase 3,Phase 2
47
Methamphetamine Approved, Illicit Phase 2,Phase 1,Not Applicable 537-46-2 10836
48
Modafinil Approved, Investigational Phase 2,Phase 1 68693-11-8 4236
49
Bupropion Approved Phase 2,Phase 1 34841-39-9, 34911-55-2 444
50
Dextroamphetamine Approved, Illicit Phase 2,Phase 1 51-64-9 5826

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse - 11 Unknown status NCT00000346 Phase 4
2 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
3 Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia Unknown status NCT02541526 Phase 3 Mirtazapine;Placebo
4 An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence Unknown status NCT02541513 Phase 3 paliparidone
5 An Open Label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and ATS Dependence Unknown status NCT02541500 Phase 3 Minocycline
6 Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland Completed NCT01100853 Phase 3 VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
7 Change the Cycle: An RCT to Prevent Injection Initiation Active, not recruiting NCT02774954 Phase 3
8 Trial of Modafinil for Methamphetamine Dependence Unknown status NCT00123370 Phase 2 Modafinil
9 A Dose Ranging Study of Modafinil for Methamphetamine Dependence Unknown status NCT00630097 Phase 2 modafinil
10 Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Completed NCT00247572 Phase 2 NRP104
11 Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2 NRP104
12 Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0) Completed NCT01888835 Phase 2 Mirtazapine;Placebo
13 Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM) Completed NCT01449565 Phase 2 Naltrexone;Placebo
14 Bupropion for the Treatment of Methamphetamine Dependence - 1 Completed NCT00069251 Phase 2 Bupropion
15 Ondansetron for the Treatment of Methamphetamine Dependence - 1 Completed NCT00040053 Phase 2 Ondansetron
16 Tyrosine for Methamphetamine Dependence - 1 Completed NCT00000322 Phase 2
17 Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men Completed NCT00856323 Phase 2 Truvada
18 Study of Medical Treatment for Methamphetamine Addiction Completed NCT00833443 Phase 2 Bupropion
19 Cannabioids as a New Intervention for Amphetamine Dependence Withdrawn NCT02952196 Phase 2 drug administration
20 A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1 Unknown status NCT00267657 Phase 1 Reserpine
21 Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1 Unknown status NCT00265278 Phase 1 Modafinil
22 To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1 Unknown status NCT00100074 Phase 1 Lobeline
23 Assessment of Interactions Between Methamphetamine and Aripiprazole - 1 Unknown status NCT00089440 Phase 1 Aripiprazole
24 Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1 Unknown status NCT00040040 Phase 1 Bupropion
25 Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1 Unknown status NCT00033072 Phase 1 Selegiline
26 Effects of Stimulant Dependence on Human Striatal Dopamine System - 15 Unknown status NCT00000350 Phase 1
27 Abuse Liability and Human Pharmacology of Mephedrone Completed NCT02232789 Phase 1 Mephedrone;3,4-methylenedioxymethamphetamine;Placebo
28 Mephedrone and Alcohol Interactions in Humans Completed NCT02294266 Phase 1 Mephedrone and alcohol;Mephedrone;Alcohol;Placebo
29 Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA) Completed NCT01386177 Phase 1 3,4-Methylenedioxymethamphetamine;Doxazosin;placebo
30 Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA) Completed NCT01136278 Phase 1 3,4-Methylenedioxymethamphetamine;Clonidine;placebo
31 Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) Completed NCT00990067 Phase 1 3,4-Methylenedioxymethamphetamine;Duloxetine;Placebo
32 Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine) Completed NCT00895804 Phase 1 MDMA;Pindolol
33 Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK) Completed NCT00886886 Phase 1 MDMA;Reboxetine, 8 mg;Placebo
34 An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers Completed NCT00713479 Phase 1 Varenicline, then placebo;Placebo, then varenicline
35 Combination of Psychosocial Intervention and Slow Prosecutions for the Treatment of Methamphetamine Abuse/Dependence Unknown status NCT01273701 Not Applicable
36 A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence Unknown status NCT01899313 Not Applicable
37 Cognitive Correlates of Substance Abuse, Part 2 - 16 Unknown status NCT00000351
38 The Novel Addiction Assessment Study in Synthetic Drugs Addiction Unknown status NCT02950376
39 A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence Completed NCT00377299 Not Applicable Citicoline;Placebo
40 Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging Completed NCT01296802 Not Applicable dexfenfluramine
41 Long-term Behavior Change - 1 Completed NCT00158197 Not Applicable
42 Functional Brain Imaging in Recreational Users of Ecstasy Completed NCT00254306
43 Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA) Completed NCT01270672 Not Applicable 3,4-Methylenedioxymethamphetamine;carvedilol;placebo
44 The Application of Music Therapy in Female Amphetamine Use Disorder Completed NCT03221283 Not Applicable
45 The Diagnostic Assessment and Intervention Study of Amphetamine Type Stimulus Completed NCT02285556 Not Applicable
46 Conflict Between Maternal Autonomy and Child Health in Substance-use Completed NCT02797990
47 Computerized Exercise to Alter Stimulant Approach Responses Recruiting NCT03902405 Not Applicable
48 The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction Recruiting NCT03318081 Not Applicable
49 Novel Intervention for Amphetamine-type Stimulants Addiction Recruiting NCT02713815 Not Applicable
50 Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward Withdrawn NCT00600145 Not Applicable Mirtazapine

Search NIH Clinical Center for Amphetamine Abuse

Cochrane evidence based reviews: amphetamine-related disorders

Genetic Tests for Amphetamine Abuse

Anatomical Context for Amphetamine Abuse

MalaCards organs/tissues related to Amphetamine Abuse:

42
Brain

Publications for Amphetamine Abuse

Articles related to Amphetamine Abuse:

(show top 50) (show all 84)
# Title Authors Year
1
Tamoxifen and amphetamine abuse: Are there therapeutic possibilities? ( 27585851 )
2017
2
Cardiovascular Complications of Acute Amphetamine Abuse: Cross-sectional study. ( 28417026 )
2017
3
Amphetamine Abuse Related Acute Myocardial Infarction. ( 26998366 )
2016
4
Facial movement disorder and dopamine imaging in a patient with amphetamine abuse. ( 27502592 )
2016
5
Superior Mesenteric Artery Syndrome Associated with Rapid Weight Loss Attributed to Amphetamine Abuse. ( 26351593 )
2015
6
Amphetamine abuse as a rare cause of recurrent LVAD pump thrombosis. ( 25545600 )
2015
7
Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment. ( 25479916 )
2015
8
Amphetamine-related disorders in psychiatric emergency service. ( 24462022 )
2014
9
Extreme Procalcitonin Elevation without Proven Bacterial Infection Related to Amphetamine Abuse. ( 24826347 )
2014
10
Factors associated with buprenorphine compared to amphetamine abuse among clients seeking treatment in Finland. ( 24560129 )
2014
11
Androgenic anabolic steroid, cocaine and amphetamine abuse and adverse cardiovascular effects. ( 24719633 )
2013
12
Efficacy of psychostimulant drugs for amphetamine abuse or dependence. ( 23996457 )
2013
13
Amphetamine abuse in Sweden: subject demographics, changes in blood concentrations over time, and the types of coingested substances. ( 23422398 )
2013
14
Amphetamine abuse in emergency department patients undergoing psychiatric evaluation. ( 22538120 )
2012
15
Acute demyelination in a person with amphetamine abuse. ( 22937385 )
2011
16
Rhabdomyolysis accompanied by spontaneous spinal subdural and subarachnoid hematoma related to amphetamine abuse. ( 20081506 )
2010
17
Modafinil treatment of amphetamine abuse in adult ADHD. ( 18562425 )
2009
18
The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007. ( 18368603 )
2008
19
Hospitalizations with amphetamine abuse among pregnant women. ( 18238971 )
2008
20
Amphetamine abuse in pregnancy: the impact on obstetric outcome. ( 17285340 )
2007
21
Contrast enhanced computer tomography of two cases of bilateral acute cortical necrosis, one of which related to amphetamine abuse. ( 16133628 )
2005
22
Coronary artery rupture associated with amphetamine abuse. ( 15316310 )
2004
23
Rapidly growing internal carotid artery aneurysm after amphetamine abuse: case report. ( 12604995 )
2003
24
Asia grapples with spreading amphetamine abuse. ( 12788585 )
2003
25
Amphetamine abuse in pregnancy: anesthetic implications. ( 12872434 )
2003
26
Massive intracerebral hematoma and extradural hematoma in amphetamine abuse. ( 11781916 )
2002
27
Altered response to intravenous thiopental and succinylcholine in acute amphetamine abuse. ( 12027859 )
2002
28
Vertebral artery dissection with amphetamine abuse. ( 17903796 )
2001
29
Dexamphetamine substitution in the treatment of amphetamine abuse: an initial investigation. ( 10723851 )
2000
30
Amphetamine abuse during pregnancy: environmental factors and outcome after 14-15 years. ( 10954143 )
2000
31
Differentiation of clobenzorex use from amphetamine abuse using the metabolite 4-hydroxyclobenzorex. ( 11043667 )
2000
32
Amphetamine abuse and intracranial haemorrhage. ( 11089483 )
2000
33
The impact of amphetamine-related disorders on community psychiatric emergency services: 1993-1997. ( 10914295 )
2000
34
Amphetamine-related disorders. ( 9805876 )
1998
35
Intracerebral haemorrhage in a young adult: consider amphetamine abuse. ( 8731653 )
1996
36
Consumption coagulopathy after amphetamine abuse in pregnancy. ( 7660777 )
1995
37
Intracerebral haemorrhage due to amphetamine abuse: report of two cases with underlying arteriovenous malformations. ( 7786436 )
1995
38
Intracerebral haemorrhage due to amphetamine abuse: report of two cases with underlying arteriovenous malformations. ( 28168906 )
1995
39
Acute myocardial infarction resulting from amphetamine abuse: a spasm-thrombus interplay? ( 7985607 )
1994
40
Holoprosencephaly and trisomy 13 in a fetus with maternal early gestational amphetamine abuse--a case report. ( 8207770 )
1993
41
Intraventricular hemorrhage following amphetamine abuse. ( 2381547 )
1990
42
Acute myocardial infarction caused by intravenous amphetamine abuse. ( 2390398 )
1990
43
Intracranial haemorrhage caused by amphetamine abuse. ( 2614776 )
1989
44
Bladder outflow obstruction secondary to intravenous amphetamine abuse. ( 2804574 )
1989
45
Update on amphetamine abuse. ( 18750614 )
1989
46
Intracerebral hemorrhage and angiographic beading following amphetamine abuse. ( 3356528 )
1988
47
Psychotic manifestations in amphetamine abuse--experimental study on the mechanism of psychotic recurrence. ( 3797582 )
1986
48
Intravenous amphetamine abuse, primary cerebral mucormycosis, and acquired immunodeficiency. ( 3998699 )
1985
49
Nails as useful materials for detection of methamphetamine or amphetamine abuse. ( 6698458 )
1984
50
Amphetamine abuse and transsexualism. ( 7108506 )
1982

Variations for Amphetamine Abuse

Expression for Amphetamine Abuse

Search GEO for disease gene expression data for Amphetamine Abuse.

Pathways for Amphetamine Abuse

GO Terms for Amphetamine Abuse

Cellular components related to Amphetamine Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.63 GRM2 GRM5 HTR1B SLC22A3 SLC6A2 SLC6A3
2 postsynaptic density membrane GO:0098839 8.96 ARC GRM5
3 neuron projection GO:0043005 8.92 GRM2 GRM5 SLC6A2 SLC6A3

Biological processes related to Amphetamine Abuse according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.73 HTR1B MAOB SLC6A2 SLC6A3
2 chemical synaptic transmission GO:0007268 9.71 GRM2 GRM5 HTR1B SLC6A2
3 response to ethanol GO:0045471 9.65 HTR1B MAOB SLC6A3
4 regulation of synaptic transmission, glutamatergic GO:0051966 9.51 GRM2 GRM5
5 positive regulation of myoblast differentiation GO:0045663 9.49 MAP3K5 MAPK14
6 G protein-coupled glutamate receptor signaling pathway GO:0007216 9.46 GRM2 GRM5
7 dopamine catabolic process GO:0042420 9.37 MAOB SLC6A3
8 p38MAPK cascade GO:0038066 9.32 MAP3K5 MAPK14
9 dopamine transport GO:0015872 9.26 SLC22A3 SLC6A3
10 dopamine uptake GO:0090494 9.16 SLC22A3 SLC6A3
11 negative regulation of serotonin secretion GO:0014063 8.96 HTR1B MAOB
12 monoamine transport GO:0015844 8.8 SLC22A3 SLC6A2 SLC6A3

Molecular functions related to Amphetamine Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glutamate receptor activity GO:0008066 9.26 GRM2 GRM5
2 neurotransmitter:sodium symporter activity GO:0005328 9.16 SLC6A2 SLC6A3
3 monoamine transmembrane transporter activity GO:0008504 8.96 SLC6A2 SLC6A3
4 dopamine:sodium symporter activity GO:0005330 8.8 SLC22A3 SLC6A2 SLC6A3

Sources for Amphetamine Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....